Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: A process for the chlorination of alkylanilines is provided allowing a highly selective chlorination in the meta-position of the aromatic ring. This is achieved by reacting a mixture comprising the alkylaniline and sulfuric acid with chlorine. This process allows a meta-chlorination with a selectivity of more than 90%.

Abstract: A process for the chlorination of alkylanilines is provided allowing a highly selective chlorination in the meta-position of the aromatic ring. This is achieved by reacting a mixture comprising the alkylaniline and sulfuric acid with chlorine. This process allows a meta-chlorination with a selectivity of more than 90%.

Abstract: Disclosed are halogenated diethyltoluenediamines of formula wherein either R1 is an amino group and R2 is chlorine or bromine, or R2 is an amino group and R1 is chlorine or bromine, and isomeric mixtures thereof. The halogenated diethyltoluenediamines of formula I are useful as chain extenders for polyurethanes and hardeners for epoxy resins having a relatively long gel time.